Postbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung Cancer

Army Medical University of People's Liberation Army

Status: Not yet enrolling

Conditions: Cachexia; Cancer

Treatments: Dietary Supplement: Placebo, 2.5 g per dose, three times per day; Dietary Supplement: Postbiotics, 2.5 g per dose, three times per day

Study type: Interventional

Funder types: Other

Identifiers

NCT07185308

DP-2025-239

Details and patient eligibility

About

This study aims to evaluate the efficacy of the oral postbiotic preparation JK-5G in improving body weight among patients with non-small-cell lung cancer (NSCLC)-related cachexia. By means of a randomized controlled trial, we will compare the between-group difference in body-weight changes between the JK-5G and placebo arms to clarify its nutritional therapeutic benefit.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years, regardless of gender.

   -

2. Patients with histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) classified as stage III-IV according to the 9th TNM edition of IASLC, who are either currently receiving or have completed chemotherapy combined with immunotherapy.

   -

3. Cachexia was diagnosed according to the international consensus criteria: involuntary weight loss >5 % within 6 months preceding screening, or BMI <20 kg/m² combined with >2 % involuntary weight loss within the same period.

   -

4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3 and an estimated life expectancy of ≥ 4 months.

   -

5. Prior to the first dose of study treatment, adequate organ function must be documented (no blood products, granulocyte-colony-stimulating factors, or thrombopoietic agents within 14 days before randomisation): 1) Absolute neutrophil count ≥ 1.5 × 10^9/L;2)Platelet count ≥ 100 × 10^9/L; 3) Haemoglobin > 90 g/L; 4) Serum creatinine < 1.5 × upper limit of normal (ULN) or creatinine clearance (Cockcroft-Gault) > 50 mL/min; 5) Total bilirubin < 1.5 × ULN (< 3 × ULN in Gilbert's syndrome) ;6) AST and ALT < 2.5 × ULN (≤ 5 × ULN if hepatic metastases present); 7) INR and aPTT ≤ 1.5 × ULN unless the participant is on therapeutic anticoagulation; 8) Left-ventricular ejection fraction (LVEF) > 50 %

   -

6. Participants must be capable of providing written informed consent and comprehending the potential risks associated with the intervention.

   -

7. Participants must demonstrate high adherence to the study protocol.

   -

8. Gastrointestinal function score of < 5.

Exclusion criteria

1. Current presence of reversible causes of reduced food intake (e.g., oral mucositis or mechanical obstruction).

   -

2. Participants who are receiving tube feeding or parenteral nutrition at the time of screening or randomization.

   -

3. Cachexia attributable to other etiologies (e.g., chronic obstructive pulmonary disease, heart failure, or HIV/AIDS).

   -

4. Major surgery within 4 weeks prior to randomization or major surgery planned during the study period.

   -

5. Initiation of systemic corticosteroid therapy within 4 weeks prior to randomization.

   -

6. Use of any appetite- or weight-enhancing agent within 30 days before randomisation, including anamorelin, megestrol acetate, cannabinoids, olanzapine, or mirtazapine.

   -

7. Use of antibiotics or probiotic-containing medications/foods within 2 weeks prior to randomization.

   -

8. Use of glucagon-like peptide-1 (GLP-1) receptor agonists for weight reduction within 30 days prior to randomization.

   -

9. Pregnant or lactating women.

   -

10. Participants who are unable to understand the study objectives or who do not agree to comply with the study requirements.

    -

11. Individuals who lack full legal capacity or whose legal capacity is restricted.

    -

12. Any medical condition that could interfere with the interpretation of study results or increase the participant's risk in the opinion of the investigators.

    -

13. Participation in any other clinical trial.

    -

14. Gastrointestinal function score of ≥ 5.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

150 participants in 2 patient groups, including a placebo group

Control group

Placebo Comparator group

Description:

Placebo + standard chemotherapy + ICIs (PD-1/PD-L1 inhibitors. The placebo was administered at the same dose and on the same schedule as the JK-5G group.

Treatment:

Dietary Supplement: Placebo, 2.5 g per dose, three times per day

JK-5G postbiotics group

Experimental group

Description:

JK-5G + standard chemotherapy + ICIs (PD-1/PD-L1 inhibitors). The intervention period for JK-5G spanned 90 days, covering four 21-day chemotherapy cycles, with a dosage of 2.5 g administered three times daily.

Treatment:

Dietary Supplement: Postbiotics, 2.5 g per dose, three times per day